Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 455 Mission Bay Boulevard South SAN FRANCISCO CA 94158 |
Tel: | 1-628-8950661 |
Website: | https://www.nektar.com |
IR: | See website |
Key People | ||
Howard W. Robin President, Chief Executive Officer, Director | Sandra A. Gardiner Interim Chief Financial Officer | Mark A. Wilson Senior Vice President, Chief Legal Officer |
Mary Tagliaferri Chief Medical Officer | Jonathan Zalevsky Chief Research and Development Officer |
Business Overview |
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection. |
Financial Overview |
For the fiscal year ended 31 December 2023, Nektar Therapeutics revenues decreased 2% to $90.1M. Net loss decreased 25% to $276.1M. Revenues reflect Rest of world segment decrease of 4% to $78.6M. Lower net loss reflects Research and development - Balancing val decrease of 47% to $100.3M (expense), Restructuring, impairment and other decrease of 77% to $15.3M (expense). |
Employees: | 137 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $90.12M as of Dec 31, 2023 |
EBITDA (TTM): | -$126.11M as of Dec 31, 2023 |
Net annual income (TTM): | -$276.06M as of Dec 31, 2023 |
Free cash flow (TTM): | -$193.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 183,617,817 as of Feb 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |